Trials / Not Yet Recruiting
Not Yet RecruitingNCT07399730
Ravulizumab Outcomes in Polish Patients With aHUS
A Non-interventional Study Evaluating Ravulizumab Treatment Outcomes in Polish Patients With Atypical Hemolytic Uremic Syndrome
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This multicenter, observational cohort study uses retrospective collection of past medical history and prospective follow-up to capture longitudinal data on the management and clinical outcomes of patients with atypical hemolytic uremic syndrome (aHUS) treated with ravulizumab as part of routine clinical practice under Poland's National Drug Program (NDP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ravulizumab | Ultomiris |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2030-12-31
- Completion
- 2030-12-31
- First posted
- 2026-02-10
- Last updated
- 2026-02-10
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07399730. Inclusion in this directory is not an endorsement.